181467-56-1
Chemical Structure
RPR121056
Synonym(s): APC
- CAS No.: 181467-56-1
- Formula:C33H38N4O8
- Molecular Weight:618.68
IUPAC Name: (S)-5-((1-(((4,11-diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl)oxy)carbonyl)piperidin-4-yl)amino)pentanoic acid
InChIKey: BSVVZICJFYZDJJ-XIFFEERXSA-N
SMILES: O=C(N1CCC(NCCCCC(O)=O)CC1)OC2=CC=C3N=C4C(CN5C(C(COC([C@@]6(CC)O)=O)=C6C=C54)=O)=C(CC)C3=C2
Biological Activity: RPR121056 (APC) is a metabolite of Irinotecan (CPT-11), which is generated by CYP3A4. Irinotecan (CPT-11) is an antineoplastic agent that inhibits topoisomerase type I, causing cell death, and is widely used in the treatment of colorectal cancer. Irinotecan also directly inhibits AChE[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
RPR121056 | 99.88% | RPR121056 (APC) is a metabolite of Irinotecan (CPT-11), which is generated by CYP3A4. Irinotecan (CPT-11) is an antineoplastic agent that inhibits topoisomerase type I, causing cell death, and is widely used in the treatment of colorectal cancer. Irinotecan also directly inhibits AChE. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
RPR121056 (Standard) | ≥98% | RPR121056 (Standard) is the analytical standard of RPR121056. This product is intended for research and analytical applications. RPR121056 (APC) is a metabolite of Irinotecan (CPT-11), which is generated by CYP3A4. Irinotecan (CPT-11) is an antineoplastic agent that inhibits topoisomerase type I, causing cell death, and is widely used in the treatment of colorectal cancer. Irinotecan also directly inhibits AChE. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
RPR121056-d3 | RPR121056-d3 is the deuterium labeled RPR121056. RPR121056 is a metabolite of Irinotecan (HY-16562), which is generated by CYP3A4. Irinotecan (CPT-11) is an antineoplastic agent that inhibits topoisomerase type I, causing cell death, and is widely used in the study of colorectal cancer. Irinotecan also directly inhibits AChE. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
